Skip to main content

Table 1 Laboratory abnormalities

From: Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma

  

All Grades n (%)

Grade 1 n (%)

Grade 2 n (%)

Grade 3/4 n (%)

p value

White blood cell count decreased

pretreatment

2 (3)

2 (3)

0 (0)

0 (0)

 

0-2 week of first cycle

10 (13)

4 (5)

6 (8)

0 (0)

0.10

First cycle

44 (56)

12 (15)

27 (34)

5 (6)

<0.01

Neutrophil count decreased

pretreatment

1 (1)

1 (1)

0 (0)

0 (0)

 

0-2 week of first cycle

4 (5)

4 (5)

0 (0)

0 (0)

0.56

First cycle

33 (42)

12 (15)

18 (23)

3 (4)

<0.01

Lymphocyte count decreased

pretreatment

22 (28)

13 (16)

7 (9)

2 (3)

 

0-2 week of first cycle

40 (51)

11 (14)

8 (10)

11 (14)

<0.01

First cycle

46 (58)

18 (23)

12 (15)

16 (20)

<0.01

Hemoglobin decreased

pretreatment

57 (72)

34 (43)

15 (19)

8 (10)

 

0-2 week of first cycle

52 (67)

31 (39)

18 (23)

3 (4)

0.30

First cycle

67 (85)

24 (30)

28 (35)

15 (19)

<0.01

Platelet count decreased

pretreatment

9 (11)

9 (11)

0 (0)

0 (0)

 

0-2 week of first cycle

45 (57)

35 (44)

6 (8)

4 (5)

<0.01

First cycle

69 (87)

33 (42)

20 (25)

16 (21)

<0.01

Creatinine increased

pretreatment

29 (36)

26 (33)

2 (3)

1 (1)

 

0-2 week of first cycle

46 (58)

42 (53)

4 (5)

0 (0)

0.04

First cycle

46 (58)

41 (52)

4 (5)

1 (1)

0.02

Aspartate aminotransferase increased

pretreatment

12 (15)

12 (15)

0 (0)

0 (0)

 

0-2 week of first cycle

42 (53)

34 (43)

6 (8)

2 (3)

<0.01

First cycle

58 (73)

47 (59)

7 (9)

4 (5)

<0.01

Alanine aminotransferase increased

pretreatment

16 (20)

16 (20)

0 (0)

0 (0)

 

0-2 week of first cycle

33 (42)

28 (35)

4 (5)

1 (1)

<0.01

First cycle

55 (70)

45 (57)

5 (6)

5 (6)

<0.01

Hypoalbuminemia

pretreatment

48 (61)

28 (35)

18 (23)

2 (3)

 

0-2 week of first cycle

69 (87)

33 (42)

30 (38)

6 (8)

<0.01

First cycle

75 (95)

27 (34)

38 (48)

10 (13)

<0.01

Blood bilirubin increased

pretreatment

0 (0)

0 (0)

0 (0)

0 (0)

 

0-2 week of first cycle

3 (4)

3 (4)

0 (0)

0 (0)

0.36

First cycle

6 (8)

5 (6)

0 (0)

1 (1)

0.02

Amylase increased

pretreatment

19 (24)

16 (20)

3 (4)

0 (0)

 

0-2 week of first cycle

29 (37)

19 (24)

8 (10)

2 (3)

0.03

First cycle

42 (53)

20 (25)

11 (14)

11 (14)

<0.01